Document is current
Any future updates will be listed below
-
Authors
Stawowczyk, Ewa
Ward, Thomas
Paoletti, Ernesto
Senni, Michele
de Arellano, Antonio Ramirez
-
Funding
Funding for this research was provided by:
CSL Vifor (n/a)
- License Information
-
More Information
Article History
Received: 14 July 2023
Accepted: 18 April 2024
First Online: 21 May 2024
Declarations
:
: Not applicable.
: Not applicable.
: A.R.dA is an employee of CSL Vifor At the time of original drafts, T.W was an employee of HEOR Ltd. E.S is an employee of HEOR Ltd. HEOR Ltd received fees from CSL Vifor in relation to this study. M.S reports consultancy fees from CSL Vifor, Novartis, Merck, Bayer, Abbott, Boehringer Ingelheim, AstraZeneca, Bioventrix, Servier, Novo Nordisk, and Cardurion, AnaCardio. E.P reports consultancy fees from CSL Vifor, AstratZeneca, Astellas, and Novartis.
